CCCC Dividend: C4 Therapeutics Inc Yield Insights

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	30	35	20	31	45	33
Revenue Growth (YoY)	-9%	75%	-35%	-31%	36%	56.99%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	37	42	42	42	33	15
Research & Development	111	110	117	117	94	78
Operating Expenses	149	152	159	160	127	93
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-118	-105	-131	-128	-83	-66
Income Tax Expense	0	0	1	--	0	0
Net Income	-119	-105	-132	-128	-83	-66
Net Income Growth	13%	-20%	3%	54%	26%	56.99%
Shares Outstanding (Diluted)	72.56	69.37	49.64	48.86	46.04	43.06
Shares Change (YoY)	4%	40%	2%	6%	7%	4%
EPS (Diluted)	-1.64	-1.51	-2.66	-2.62	-1.82	-1.54
EPS Growth	9%	-43%	2%	44%	18%	51%
Free Cash Flow	-95	-65	-108	-111	-88	-67
Free Cash Flow Per Share	-1.3	-0.93	-2.17	-2.27	-1.91	-1.55
Gross Margin	--	--	--	--	--	--
Operating Margin	-396.66%	-334.28%	-695%	-416.12%	-182.22%	-181.81%
Profit Margin	-396.66%	-300%	-660%	-412.9%	-184.44%	-200%
Free Cash Flow Margin	-316.66%	-185.71%	-540%	-358.06%	-195.55%	-203.03%
EBITDA	-117	-116	-138	-128	-81	-59
EBITDA Margin	-390%	-331.42%	-690%	-412.9%	-180%	-178.78%
D&A For EBITDA	2	1	1	1	1	1
EBIT	-119	-117	-139	-129	-82	-60
EBIT Margin	-396.66%	-334.28%	-695%	-416.12%	-182.22%	-181.81%
Effective Tax Rate	0%	0%	-0.76%	--	0%	0%

C4 Therapeutics Inc (CCCC) Price